Graft failure is less frequent but more devastating than GVHD. With the latter becoming more treatable, will SCT be used more, or will fear of the former prevent noticeable changes in practice? [for comparison, I'm strongly "Don't know"]
I would love to participate! However, yahoo is a pretty bad platform for discussion for several reasons, lot the least being the formatting. Hard to tell who is replying to whom.
I'd be happy to address any comments or questions on SA, too.
As to your specific comment here, I think that's an interesting point. Certainly ruxolitinib is getting a lot of off-label use, enough to have run a whole retrospective analysis.
Certainly in neoplasia like MF where allo-SCT is the standard, anything to reduce GVHD is a big boon. It's improved a lot over the last 20 years or so. Myeloma, though? I'm not sure. Auto-SCT works well, and there's a whole new world of options opening up now that may put off SCT for many. It would be my hope that we can forego it altogether, especially given the advanced age of myeloma patients.
But allo-SCT remains and will remain an important treatment option for other forms of leukemia. So I am very excited about ruxolitinib here. It could move very quickly indeed.
Would you be wiling to participate here regularly (or at least occasionally)? We can use more intelligent discussion.
I think ruxo is becoming / will become the standard of care for acute GVHD before breakthrough designation can have any effect...has a lot to do with physician personalities. The kinds of oncos who do a lot of SCTs are also fairly active in using available drugs off-label. Short-term / cash, I think the big effect of the designation is the couple $tens of millions it's likely to shave off the expense of getting the label expansion.
I think the risk of transplant failure will be enough to prevent large expansion of the use of SCT soon, but better treatment for GVHD will tilt the choice between autologous and mixed autologous / heterologous SCTs where that choice is a live one. That may be a big deal for myeloma treatment. (A LITTLE anti-host reaction from the foreign-derived marrow helps control the cancer)
Hello, this is from an article I wrote on Seeking Alpha, and I encourage everyone to go read it for more information!
no sweat--only down 4.68. Happy days right around the corner. Huuuh! ugh---zzzzzzzzz
Awww....look who woke up....Sleepy!!! Hope you made some dollars with me on some BREXIT trades this week....oh ya...you missed it...you were sleeping!! Always bet on Sovereign votes!!
margin calls? now you are smoking TJ - go hold Dopey and Sleepy's hands would ya...they need it!!
Good luck with that prediction Dopey!! Lost what we gained yesterday...not a bad trade off all things considered. Ping me if our GEM goes below $8.00 - until then you're wasting your time and effort!!
Restless in Detroit I know.
it has been falling off a cliff since noon, i would only expect more to happen, russell is based on mkt cap, thus incyte will have lots of presure as market cap was much higher last year
O ton of bricks is falling on INCY and it will be bruised and beaten back down into the 60's.....